CDMO firm ZhiXiang Biologics raises over 500 million yuan in Series C funding to accelerate biopharma R&D for global clients

Recently, ZhiXiang Biologics (Suzhou) Co., Ltd. (hereinafter referred to as "ZhiXiang Biologics") announced the completion of its Series C financing, raising over 500 million RMB. This round was co-led by Gaorong Ventures and Qingsong Capital, with participation from Fuhui Ventures, CITIC Bank Investment Beijing, Founder Securities Investment, and Wenhua Haihui.

The proceeds will be used to rapidly expand commercial production capacity, comprehensively upgrade its technology platforms, advance international business strategy, and grow its talent team.

Focused on Large-Molecule Biopharmaceutical Process Development and Commercial Manufacturing

Founded in April 2018, ZhiXiang Biologics focuses on process development and large-scale commercial manufacturing CDMO services for large-molecule biopharmaceuticals. With continuous breakthroughs in cutting-edge process development technology platforms, it is one of the few CDMO enterprises possessing core technologies, mass production capabilities, and closed-loop commercialization competence.

ZhiXiang Biologics operates seven CDMO technology platforms, covering GMP manufacturing, ADC, multi-culture systems, proprietary cell line development, developability analysis, viral safety testing, and formulation development.

The company has production facilities in Suzhou Xiangcheng High-Tech Zone, Suzhou Industrial Park, and Changshu High-Tech Zone. All sites have launched flexible production line expansion projects, with total planned capacity reaching 220,000 liters by 2023 — giving it globally leading production scale and cost advantages.

Extreme R&D Timelines and Supply Chain Systems to Fully Empower Novel Drug Clients

ZhiXiang Biologics' service portfolio covers monoclonal antibodies, bispecific antibodies, multispecific antibodies, fusion proteins, vaccines, ADCs, and more. It is also one of the few domestic companies capable of manufacturing ADC drugs.

Through extreme project R&D timelines and flexible, innovative process development, ZhiXiang Biologics fully empowers novel drug clients to seize market opportunities. For example, by adopting platformized monoclonal antibody production processes to shorten process development time, one trispecific antibody project went from molecule confirmation to delivery of 200L samples in just three months. By using platformized production materials to reduce procurement lead times, a bispecific antibody project moved from cell transfer to sample delivery in only seven weeks.

Beyond its significant speed advantages, ZhiXiang Biologics is gradually growing into a powerful and reliable "biopharmaceutical manufacturer." The company internally strengthens its quality system while continuously optimizing and upgrading processes. Additionally, it deepens strategic partnerships with domestic enterprises, building a supply chain system that combines collaborative development with independent R&D to achieve high-level control over commercial production costs — thereby effectively helping clients reduce total R&D costs, integrate resources with high quality, and providing more competitive comprehensive solutions.

Going forward, ZhiXiang Biologics will continue to deepen its focus in specialized segments, continuously expanding its corporate scale and overall production capacity, and further strengthening its "moat" through differentiated services to enhance international competitiveness.

Enhancing International Competitiveness Amid Rapid Growth in the Biopharmaceutical CDMO Industry

Currently, the global biopharmaceutical market is in a period of rapid development, with market size growing year by year and projected to exceed $500 billion by 2025. In China, both the number of biopharmaceutical innovation applications and IND approvals continue to climb.

Against this backdrop, the biopharmaceutical CDMO industry is entering a golden era of growth. Industry data shows that the global biopharmaceutical CDMO market has a compound annual growth rate exceeding 20%, while China's large-molecule drug CDMO market maintains a 40% growth rate.

Li Zhi, CEO of ZhiXiang Biologics, stated: "We are committed to accelerating the market launch of more novel drugs, and have accumulated extensive experience in practice to find optimal pathways for full-process services from IND to BLA. ZhiXiang Biologics is technologically leading, and under our full-industry-chain layout, we have rapidly achieved scaled production and gained broad industry recognition, contributing to China's biopharmaceutical 'smart' manufacturing. We will also maintain our long-term development vision and values, helping clients with decision-making challenges, preparing for long-term growth, and adhering to sustainable business practices. We thank our investors for their trust and our clients for their support. We will continue to focus on the CDMO field and explore unlimited possibilities, aiming to make ZhiXiang Biologics a leading global CDMO enterprise to benefit more patients."

A project lead at Gaorong Ventures commented: "As more biopharmaceuticals globally advance from early-stage R&D through to commercial production, and platform technologies continue to expand horizontally from monoclonal antibodies to multispecific antibodies, fusion proteins, ADCs, and beyond, these trends present both enormous opportunities and new challenges for CDMO enterprises. As a one-stop CDMO service platform, ZhiXiang Biologics provides clients with solutions that are both fast and stable through extreme R&D timelines and a mature supply chain system — swift as the wind, steady as the forest. This is supported by ZhiXiang Biologics' experienced team, powerful technology platforms, and scaled, systematic supply chain. We are also optimistic about ZhiXiang Biologics' next steps in further expanding capacity and its internationalization roadmap, empowering more clients globally in their novel drug R&D processes."